Compass Therapeutics, Inc. SEC filings CMPX
Compass Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to May 30, 2018. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 1, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 27, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Jan 6, 2026 | Jan 6, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 13, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 1, 2025 | Apr 1, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Jan 8, 2025 | Jan 8, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 10, 2024 | Dec 9, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 28, 2024 | May 28, 2024 |
| 8-K |
Current report
Results of operations
|
May 13, 2024 | May 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 25, 2024 | Apr 25, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 9, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 5, 2024 | Jan 5, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2023 | Jun 15, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 24, 2023 | Apr 21, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 24, 2023 | Feb 20, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 10, 2023 | Feb 8, 2023 |
| 8-K |
Current report
Other events
|
Jan 19, 2023 | Jan 19, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 29, 2022 | Nov 29, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Nov 2, 2022 | Nov 2, 2022 |
| 8-K |
Current report
Officer or director change
|
Aug 19, 2022 | Aug 17, 2022 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Aug 1, 2022 | Jul 22, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 31, 2022 | May 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
May 4, 2022 | May 4, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 26, 2022 | Apr 22, 2022 |
| 8-K |
Current report
Officer or director change
|
Feb 25, 2022 | Feb 22, 2022 |
| 8-K |
Current report
Other events
|
Jan 20, 2022 | Jan 20, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 21, 2021 | Dec 20, 2021 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 3, 2021 | Nov 1, 2021 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 1, 2021 | Nov 1, 2021 |
| 8-K |
Current report
Other events
|
Oct 8, 2021 | Oct 8, 2021 |
| 8-K/A | Amended current report | Aug 5, 2021 | Jun 25, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Officer or director change, Other events
|
Jun 30, 2021 | Jun 25, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2021 | Jun 3, 2021 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 13, 2021 | May 13, 2021 |
| 8-K |
Current report
Officer or director change
|
Apr 19, 2021 | Apr 14, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 17, 2020 | Dec 12, 2020 |
| 8-K |
Current report
Officer or director change
|
Sep 15, 2020 | Sep 10, 2020 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Jul 31, 2020 | Jun 17, 2020 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change
|
Jun 23, 2020 | Jun 17, 2020 |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CMPX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1738021
- Former names
- Olivia Ventures, Inc. (until Jun 8, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.